2021 Revenues ($USD) : $16,071,700,000
2021 R&D spend : $2,908,100,000
2021 Number of Employees : 10,368
Fiscal Year End : 12/31/2021
Leader : CEO Leonard Schleifer

The biotech Regeneron Pharmaceuticals fared well in 2021. Revenues, excluding the company's COVID-19 antibody cocktail, were up by 19%. However, the COVID-19 antibody REGN-COV2 did not perform well against the omicron variant, leading the Tarrybown, New York–based company back to the drawing board. REGEN-COV2 was no longer authorized in any U.S. region in early 2022. Sales of the macular degeneration treatment Eylea (aflibercept) grew 19% to $9.4 billion in 2021, while sales of the monoclonal antibody Dupixent (dupilumab) hit $6.2 billion, driving 53% of its overall growth in 2021. —BB